AIDS Malignancy Consortium

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Recruiting

Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma

Jul 9, 2026

Completed

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

Earlier

Jun 24, 2026TrialEpcoritamab in Combination With Dose Adjusted R-EPOCH for High Risk Burkitt Lymphoma (BL) (BEDROCK Study)

Nov 7, 2023TrialTrial of Ixazomib for Kaposi Sarcoma

May 31, 2022TrialTesting the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

May 24, 2021TrialA Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Apr 26, 2021TrialPomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

Jul 31, 2019TrialHPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

4 more events

Oct 10, 2018TrialEvaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine

Feb 13, 2018TrialsEphB4-HSA in Treating Patients With Kaposi Sarcoma

Mar 13, 2017TrialNelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

Sep 15, 2016TrialIntravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)